-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $4

Benzinga·11/11/2026 19:40:10
Listen to the news
Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $7 to $4.